Emerging Cannabis Markets: Real Opportunity, Real Whiplash
Photo by David Vives via Unsplash.
Every industry conference deck for the last three years has had some version of the same slide: a world map with arrows pointing outward, labeled something like "next frontier" or "global opportunity," usually with Thailand, Germany, and a scattering of Latin American flags highlighted in green. The pitch is simple and mostly true — North American markets are maturing and margin-compressed, so the growth has to come from somewhere else. What that slide never shows is how fast the arrows can reverse.
The last 18 months gave us a real-time demonstration. Thailand went from the region's loudest cannabis liberalization story to a case study in regulatory retreat, tightening rules on the same industry it had decriminalized less than four years earlier. Germany's import channel for medical cannabis survived a challenge from its own upper house of parliament, but survived is doing a lot of work in that sentence — the legal footing under it is still being negotiated, not settled. And hanging over all of it is a supply problem: producers across multiple continents are scaling cultivation on the assumption that import markets will keep absorbing it, a bet nobody has actually tested yet.
None of this means international cannabis expansion is a mirage. It means the opportunity is real but considerably narrower than the conference-slide version, and it's showing up in a different place than most people expected — not in retail, not in tourism, but in unglamorous, contract-driven, pharmaceutical-grade export supply chains. The pattern across markets right now isn't steady liberalization. It's whiplash.
Thailand's Boom and Bust, in Numbers
As of early 2026, roughly 11,100 Thai cannabis shop licenses remain active, while over 7,200 have already shut down; nearly 9,800 more licenses are set to expire in 2026 and 2027, signaling continued turnover in the industry.
Thailand's cannabis story has moved fast enough to whiplash anyone who stopped paying attention for a quarter. Medical cannabis became legal there in 2018, and in June 2022, under then-health minister Anutin Charnvirakul, the country decriminalized broader cannabis use, effectively opening the door to a retail boom that produced thousands of dispensaries in city centers and tourist districts almost overnight. It was, at the time, treated as the boldest cannabis opening in Asia, and Anutin became the political face of it.
That personal association is what makes what happened next so instructive. Anutin became prime minister in September 2025 and was reconfirmed after a March 2026 election — meaning the architect of Thailand's cannabis opening now runs the government. And his own administration's policy on cannabis has still been walked back. Since June 25, 2025, cannabis flower has been classified as a controlled herb, meaning consumers need a PT33 prescription from a certified practitioner and dispensaries operate under medical supervision rather than open retail. This is not a minor paperwork adjustment; it's a reclassification of the entire consumer-facing model that decriminalization had built.
The numbers show the scale of the shakeout. Of 18,433 cannabis shops that had been operating nationwide, 7,297 had shut down as of February 2026 after failing to renew their licenses under the stricter rules, leaving 11,136 still open. That's not the end of it, either — another 4,587 licenses are set to expire in 2026, with 5,210 more following in 2027, which means the industry is still mid-contraction, not post-contraction. Meanwhile, the comprehensive Cannabis and Hemp Act that would give the industry a stable long-term legal framework still hadn't passed as of July 2026, despite Minister Pattana Promphat pushing the draft forward on July 7 of that year. Thailand has spent four years oscillating between opening and tightening without ever landing on a durable statute, and that instability is the actual headline, more than any single rule change.
The New April 2026 Rules: Raising the Bar on Purpose
Photo by Pexels via Pixabay.
The April 2026 rules are worth reading closely because they show exactly what kind of industry Thailand's government has decided it wants to regulate — and it isn't the one that grew up after 2022. A ministerial regulation published in the Royal Gazette on April 30, 2026 requires anyone holding a cannabis-flower license to have medical, pharmaceutical, or licensed-traditional-healer credentials. That single requirement disqualifies a huge share of the operators who opened shops in the post-decriminalization gold rush, since most of those businesses were built by entrepreneurs and tourism operators, not clinicians.
The physical requirements layered on top reinforce the same direction: dedicated elevated storage, odour and smoke control systems, and DTAM-trained staff required on site during operating hours. DTAM is Thailand's Department of Thai Traditional and Alternative Medicine, and its involvement signals the government is folding cannabis back into a medical and traditional-medicine framework rather than treating it as a standalone consumer category. In effect, Thailand is re-professionalizing an industry that, for a few chaotic years, grew informally around thousands of small retail storefronts with minimal credentialing.
The export side got its own sharp edge. From June 17, 2026, exporting cannabis without proper authorization carries a fine of 30,000 baht (roughly £680) per kilogram, with up to two years of detention for anyone unable to pay. That's a serious deterrent aimed squarely at the informal export activity that had presumably grown alongside the domestic retail boom.
Put together, the regulatory direction is unmistakable and consistent: Thailand is converting what had become a recreational-adjacent gray market into a licensed medical-and-export industry with real barriers to entry. There's a useful historical parallel here — several early US medical marijuana states went through a similar tightening after chaotic initial openings, adding residency requirements, vertical integration rules, and licensing caps once the first wave of loosely regulated dispensaries created problems regulators hadn't anticipated. States like Colorado and California took years to work through that cycle. Thailand is compressing a comparable correction into roughly four years, which is part of why it's been so disorienting to watch from the outside.
Why Investors Still Aren't Writing Thailand Off
Photo by Kenny Orr via Unsplash.
Given all that, it would be reasonable to assume institutional capital is simply walking away from Thailand. It isn't, and the reasoning behind that is worth taking seriously rather than dismissing as denial. A Prohibition Partners analyst flagged Thailand in 2026 as a new force entering the international medical cannabis supply chain — not despite the regulatory tightening, but in some ways because of it.
The underlying case for Thailand hasn't actually changed. It has abundant natural resources, a tropical climate well suited to outdoor and low-cost greenhouse cultivation, and operating costs that undercut Europe or North America by a wide margin. None of the April 2026 rules touch any of that. What they touch is who's allowed to hold a license and how the product moves, which is exactly the kind of friction that tends to consolidate an industry rather than kill it. A growing base of cultivators has already been producing for medical export markets rather than domestic retail, and that segment is arguably the one least disrupted by rules aimed at storefront dispensaries and consumer access.
The bet serious investors are making is that this consolidation strengthens the operators who survive it. Clearing out thousands of undercapitalized retail shops that couldn't meet DTAM staffing or storage requirements removes competitors, tightens supply discipline, and leaves the field to players who can actually meet pharmaceutical-grade standards for export. That's a coherent thesis, and it has precedent in how consolidation played out in maturing US state markets.
The counter-case deserves equal weight, though. A stalled Cannabis and Hemp Act means the legal foundation exporters would need for long-term supply contracts still doesn't exist in statute — everything currently rests on ministerial regulations that can be rewritten as fast as the April 2026 rules were introduced. Policy could tighten further under continued political or law-enforcement pressure, and nothing about Thailand's last four years suggests the rulemaking has found a stable resting point. The realistic opportunity here looks like B2B cultivation-for-export and pharmaceutical-grade processing aimed at other countries' medical systems, not retail storefronts or cannabis-tourism ventures, both of which are precisely the model Thailand's government has just spent a year dismantling.
Germany, Australia, and the Fragility of Import Demand
Photo by Felix-Mittermeier via Pixabay.
Germany and Australia matter to this conversation for a specific reason: they're among the largest medical cannabis import markets outside North America, which makes them bellwethers for anyone exporting flower or extract on a pharmaceutical model. If demand in those two markets is stable, it validates the export thesis everyone from Thailand to Latin America is now chasing. If it isn't, a lot of that cultivation capacity has nowhere obvious to go.
The signal from Germany in the last year has been genuinely mixed. Germany's Cabinet rejected a Bundesrat push to shut down cross-border EU prescriptions, which preserved a key access channel that patients and importers rely on — a real win, and one worth noting plainly as fact rather than speculation. But the proposed delivery restrictions that prompted the fight in the first place still lack clear penalty mechanisms attached to them, which means the legal picture around cross-border prescribing remains unsettled rather than resolved. A rejected proposal isn't the same as a closed question; it's a pause in an argument that Germany's federal and state-level bodies are still actively having.
Layered on top of that political uncertainty is a structural one. Lawrence Purkiss, an analyst at Prohibition Partners, has warned that oversupply is likely to become a recurring theme as producers in multiple countries scale cultivation faster than import markets can absorb the product. That's a reasoned extrapolation from current production trends rather than a confirmed outcome, but it's the kind of imbalance that shows up reliably whenever a commodity attracts simultaneous investment across several exporting countries without a corresponding increase in demand.
The risk for exporters betting on Europe is straightforward: they're pricing in stable demand from a market where the demand side is being actively negotiated, country by country and at the EU level, in real time. A political win like the Cabinet's rejection of the Bundesrat push is genuinely good news for import channels today. It is not, however, a settled market in the way a five-year supply contract would want it to be — and treating it as settled is where exporters get exposed.
Latin America and Canada: Two Different Export Playbooks
Photo by CDC via Unsplash.
Latin America's biggest medical cannabis markets are building something noticeably different from the US retail template, and the direction they've chosen tells you where the smart money in this industry is actually pointing. Brazil, Colombia, and Mexico are all expanding their medical cannabis frameworks, but each is building toward pharmaceutical and export-oriented models rather than the dispensary-on-every-corner approach that defined early US state legalization. Colombia in particular has leaned into its cultivation cost advantages to position itself as a supply base for other countries' medical systems rather than trying to build a large domestic consumer market from scratch.
That's the same pivot Thailand has been forced into by regulation — toward B2B export rather than domestic consumer retail — which suggests this isn't a coincidence specific to one country's politics but a broader global pattern. When cannabis markets mature past their first liberalization wave, the durable business model that keeps showing up is contract cultivation and processing for pharmaceutical export, not consumer-facing retail.
Canada offers a useful counterpoint, because it shows that even an established, well-regulated exporter isn't immune to trade friction. Israel has repeatedly investigated Canadian producers over alleged dumping of cannabis flower — selling into the Israeli market below fair value in ways that undercut domestic and other foreign suppliers. Canada has one of the most mature legal cannabis regimes in the world, with years of GMP-equivalent production experience behind it, and it has still faced these anti-dumping actions more than once.
The pattern that emerges is worth sitting with: as more countries chase the same export-oriented medical model simultaneously — Thailand, Colombia, Brazil, Canada, and others all effectively competing to supply the same pool of import markets like Germany and Australia — trade friction and anti-dumping investigations become a recurring risk rather than a one-off news item. For new entrants sizing up which markets to build in, the lesson isn't just about local regulation. It's that market access itself, even for established players, can be challenged from the outside by the very countries they're trying to sell into.
What This Means for Anyone Actually Building a Business Here
Photo by cottonbro studio via Pexels.
Pull all five markets together and a fairly clear operating thesis emerges for anyone actually trying to build a business here rather than just write about it. The realistic opportunity in emerging markets right now is cultivation and processing for medical and pharmaceutical export, not consumer-facing retail or cannabis tourism. Every market examined here — Thailand, Germany's import channel, Colombia, Brazil, Canada — is converging on that same B2B, GMP-adjacent model, whether by regulatory force or deliberate strategy.
The whiplash pattern is now recognizable enough to plan around instead of being blindsided by. Rapid opening — Thailand's 2022 decriminalization, Germany's broader cannabis reforms — tends to get followed by tightening once informal markets outpace the regulatory and enforcement capacity built to oversee them. That's not a one-off; it's the second time in this piece alone we've seen the sequence play out, and it echoes the earlier US state-level tightening cycles too. Any business plan premised on today's rules staying put is really a bet against a pattern with multiple recent precedents.
Oversupply risk changes who capital should back. If Purkiss's warning about production outpacing import absorption holds, then operators without existing GMP or EU-GMP certification and without diversified export contracts across multiple destination markets are the most exposed — they're the ones competing hardest for shrinking margin in a crowded field. Investors and operators alike should weight toward businesses that already look and act like pharmaceutical suppliers, not like the last cycle's dispensary chains.
Maybe the single clearest data point in all of this is a political one: Thailand's own reform architect became prime minister and still couldn't hold his original cannabis policy together against bureaucratic and law-enforcement pushback. That says something uncomfortable about how fragile even genuinely popular cannabis reforms are once they run into the machinery of a state that never fully built the institutions to regulate them. The practical takeaway is to treat any single country's current cannabis rules as a snapshot, not a foundation — and to structure contracts and operations on the assumption that another regulatory cycle is coming within two to three years, because in every market covered here, it already has.
Look at where the headlines cluster and where the durable business footing actually sits, and they're not the same map. Thailand generates the most coverage precisely because its swings are so dramatic — legal in 2018, decriminalized in 2022, reversed through 2025 and 2026 even under the prime minister who built the original policy. Germany generates coverage because its import channel is the subject of an ongoing political fight, not a finished one. Durability, when it shows up at all right now, is showing up somewhere quieter: narrow, export-oriented, pharmaceutical-grade niches in Colombia, Brazil, and the surviving segment of Thailand's own cultivation base.
Thailand's full arc is the clearest evidence available that fast liberalization without the institutional capacity to regulate it invites an equally fast correction. Four years from open decriminalization to a controlled-herb prescription regime, with 7,297 shops already shuttered and thousands more license renewals still pending through 2027, isn't a story about one bad policy decision. It's a story about a government building consumer access faster than it built the enforcement and credentialing infrastructure to sustain it — and eventually having to claw that gap back closed.
The next two years will likely do the sorting that boosterish market-size slides never do. Operators who built for compliance, GMP certification, and export diversification across several destination countries will be positioned to absorb whatever oversupply and trade-friction pressure comes next. Operators who built for a regulatory moment — Thailand's 2022 opening, a particular reading of Germany's import rules — that has already partially closed will find the ground has moved under them again, probably before their next funding round.
